JSPR on Nasdaq

Jasper Therapeutics, Inc.

American biological products company based in Redwood City.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerJSPR on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
HeadquartersDE
Incorporated inDE²
Business address2200 Bridge Pkwy Suite #102, Redwood City, Ca 94065²
Filer category, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷-$83.9M in 2025

Net income⁴⁵³⁶⁷-$75.8M in 2025+139% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Research and development	$63.1M	$55.8M
General and administrative	$20.8M	$20.4M
Total operating expenses	$83.9M	$76.2M
Loss from operations	-$83.9M	-$76.2M
Interest income	$1.7M	$5.1M
Change in fair value of warrant liability	$8.5M
Other expense, net	-$2.2M	-$88.0K
Total other income, net	$8.1M	$5.0M
Net loss and comprehensive loss	-$75.8M	-$71.3M
Net loss per share attributable to common stockholders, basic (in Dollars per share)	-$3.95	-$4.89
Net loss per share attributable to common stockholders, diluted (in Dollars per share)	-$3.95	-$4.89
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in Shares)	19.2M shares	14.6M shares
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares)	19.2M shares	14.6M shares

Total assets¹⁰⁴⁵³⁶⁷$35.8M in 2025−65% since 2019

Total liabilities¹⁰⁴⁵³⁶⁷$31.6M in 2025+191% since 2019

Shareholders’ equity⁴⁵³⁶⁷$4.2M in 2025

Cash¹⁰⁴⁵³⁶⁷$28.7M in 2025+2266% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$28.7M	$71.6M
Prepaid expenses and other current assets	$6.0M	$4.2M
Total current assets	$34.6M	$75.8M
Property and equipment, net	$102.0K	$1.9M
Operating lease right-of-use assets	$502.0K	$976.0K
Restricted cash	$417.0K	$417.0K
Other non-current assets	$113.0K	$820.0K
Total assets	$35.8M	$79.9M
Accounts payable	$6.2M	$4.0M
Current portion of operating lease liabilities	$1.2M	$1.1M
Accrued expenses and other current liabilities	$5.7M	$10.1M
Total current liabilities	$13.2M	$15.2M
Non-current portion of operating lease liabilities		$724.0K
Warrant liability	$16.2M
Other non-current liabilities	$2.3M	$2.3M
Total liabilities	$31.6M	$18.2M
Common stock: $0.0001 par value 492,000,000 shares authorized at December 31, 2025 and 2024; 27,996,819 and 15,022,122 shares issued and outstanding at December 31, 2025 and 2024, respectively	$3.0K	$2.0K
Additional paid-in capital	$320.8M	$302.5M
Accumulated deficit	-$316.7M	-$240.9M
Total stockholders equity	$4.2M	$61.7M	$78.4M
Total liabilities and stockholders equity	$35.8M	$79.9M
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	10.0M shares	10.0M shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	492.0M shares	492.0M shares
Common stock, shares issued (in Shares)	28.0M shares	15.0M shares
Common stock, shares outstanding (in Shares)	28.0M shares	15.0M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$28.7M	$71.6M
Prepaid expenses and other current assets	$6.0M	$4.2M
Total current assets	$34.6M	$75.8M
Property and equipment, net	$102.0K	$1.9M
Operating lease right-of-use assets	$502.0K	$976.0K
Restricted cash	$417.0K	$417.0K
Other non-current assets	$113.0K	$820.0K
Total assets	$35.8M	$79.9M
Accounts payable	$6.2M	$4.0M
Current portion of operating lease liabilities	$1.2M	$1.1M
Accrued expenses and other current liabilities	$5.7M	$10.1M
Total current liabilities	$13.2M	$15.2M
Non-current portion of operating lease liabilities		$724.0K
Warrant liability	$16.2M
Other non-current liabilities	$2.3M	$2.3M
Total liabilities	$31.6M	$18.2M
Common stock: $0.0001 par value 492,000,000 shares authorized at December 31, 2025 and 2024; 27,996,819 and 15,022,122 shares issued and outstanding at December 31, 2025 and 2024, respectively	$3.0K	$2.0K
Additional paid-in capital	$320.8M	$302.5M
Accumulated deficit	-$316.7M	-$240.9M
Total stockholders equity	$4.2M	$61.7M	$78.4M
Total liabilities and stockholders equity	$35.8M	$79.9M
Preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in Shares)	10.0M shares	10.0M shares
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	492.0M shares	492.0M shares
Common stock, shares issued (in Shares)	28.0M shares	15.0M shares
Common stock, shares outstanding (in Shares)	28.0M shares	15.0M shares

Cash from operations⁴⁵³⁶⁷-$77.2M in 2025+322% since 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Net loss	-$75.8M	-$71.3M
Depreciation and amortization expense	$1.1M	$1.4M
Impairment of long-lived assets	$1.1M
Non-cash lease expense	$1.2M	$491.0K
Stock-based compensation expense	$6.7M	$6.6M
Change in fair value of warrant liability	-$8.5M
Offering costs recognized in other expense, net	$2.0M
Prepaid expenses and other current assets	-$1.8M	-$2.1M
Other non-current assets	$707.0K	$523.0K
Accounts payable	$2.2M	-$122.0K
Accrued expenses and other current liabilities	-$4.4M	$2.9M
Operating lease liability	-$1.7M	-$973.0K
Net cash used in operating activities	-$77.2M	-$62.6M
Purchases of property and equipment	-$7.0K	-$552.0K
Proceeds from sales of property and equipment	$12.0K	$20.0K
Net cash provided by (used in) investing activities	$5.0K	-$532.0K
Proceeds from issuance of common stock through ATM offering, net	$6.5M
Proceeds from issuance of common stock and warrants through underwritten offering, net	$27.5M	$47.2M
Proceeds from exercise of common stock options		$329.0K
Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plan	$243.0K	$360.0K
Net cash provided by financing activities	$34.2M	$47.9M
Net decrease in cash, cash equivalents and restricted cash	-$42.9M	-$15.2M
Right-of-use asset obtained in exchange for lease liabilities	$1.1M
Warrant liability recognized in connection with underwritten offering	$24.7M

Compare Jasper Therapeutics, Inc. with another company

Leadership

Who has led Jasper Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

20202025

Chief executive officerJeetinder Singh Mahal Feb 10, 2026 to now¹¹
Chief executive officerRon Martell Mar 21, 2022 to Feb 10, 2026¹²
Chief executive officerWilliam Lis Oct 1, 2021 to Oct 1, 2021¹³
Chief executive officerBalaji Venkataraman Nov 19, 2019 to Jan 7, 2020¹⁴
PresidentJeetinder Singh Mahal Feb 10, 2026 to now¹¹
PresidentRon Martell Mar 21, 2022 to Feb 10, 2026¹²
PresidentVishal Kapoor Jan 9, 2020 to Jan 9, 2020¹⁵
Chief financial officerHerb Cross Sep 26, 2023 to now¹⁶
Chief financial officerJeetinder Singh Mahal Mar 23, 2022 to Mar 23, 2022¹⁷
Chief financial officerKenneth F. Clifford Nov 19, 2019 to Jan 7, 2020¹⁸
Chief operating officerMatthew E. Ros Jul 22, 2026 to now¹⁹
Chief operating officerJeetinder Singh Mahal Mar 23, 2022 to Jul 22, 2026¹⁷

Board members and other officers (25)

EVP, Head of R&DWenru Song Jul 22, 2026 to now²⁰
Chief Medical OfficerGreg Keenan Jul 23, 2026 to now²¹
Chief Medical OfficerEdwin Jonathan Tucker Jun 13, 2023 to now²²
OfficerWilliam Lis Mar 23, 2022 to Mar 23, 2022²³
OfficerJeetinder Singh Mahal Oct 1, 2021 to Jun 13, 2023²⁴
EVP, Research and DevelopmentKevin N. Heller Oct 1, 2021 to Mar 23, 2022²⁵
Board memberJeetinder Singh Mahal Feb 10, 2026 to now¹¹
Board memberPatrick J. Crutcher Jul 20, 2026 to now²⁶
Board memberSvetlana Lucas Jun 20, 2024 to now²⁷
Board memberVishal Kapoor Feb 17, 2023 to now²⁸
Board memberScott C. Brun Jun 20, 2023 to now²⁹
Board memberThomas G. Wiggans Nov 2, 2023 to now³⁰
Board memberRon Martell Mar 21, 2022 to now¹²
Board memberAnna Louise French Oct 1, 2021 to Jun 10, 2024³¹
Board memberChris Nolet Oct 1, 2021 to now³²
Board memberJudith Anne Shizuru Oct 1, 2021 to now³³
Board memberKurt Von Emster Oct 1, 2021 to now³⁴
Board memberLawrence Otto Klein Oct 1, 2021 to Jun 8, 2023³⁵
Board memberWilliam Lis Oct 1, 2021 to Oct 13, 2023¹³
Board memberBalaji Venkataraman Nov 19, 2019 to Jan 7, 2020¹⁴
Board memberErnest Mario Nov 19, 2019 to Nov 19, 2019³⁶
Board memberFredric N. Eshelman Nov 19, 2019 to Nov 19, 2019³⁷
Board memberGlenn Reicin Nov 19, 2019 to Nov 19, 2019³⁸
Board memberHoward I. Hoffen Nov 19, 2019 to Jan 7, 2020³⁹
Board memberPeter R. Dolan Nov 19, 2019 to Nov 19, 2019⁴⁰

Former names

Amplitude Healthcare Acquisition CorpSep 13, 2019 to Sep 29, 2021²

Timeline

Feb 10, 2026New chief executive Jeetinder Singh Mahal becomes CEO¹¹
Mar 21, 2022New chief executive Ron Martell becomes CEO¹²
Oct 1, 2021New chief executive William Lis becomes CEO¹³
Nov 19, 2019New chief executive Balaji Venkataraman becomes CEO¹⁴

Filings

358 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 78 major events, 125 insider forms, 55 large holders, 1 private raises, 78 other. The latest 20:

Oct 15, 20268-K CURRENT REPORT EDGAR
Oct 14, 2026S-3 REGISTRATION STATEMENT EDGAR
Oct 9, 2026PRE 14A PROXY STATEMENT EDGAR
Oct 7, 20268-K CURRENT REPORT EDGAR
Oct 7, 2026SC TO-I EDGAR
Oct 5, 20268-K CURRENT REPORT EDGAR
Oct 5, 20268-K/A AMENDMENT NO. 2 TO FORM 8-K EDGAR
Oct 1, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
Sep 28, 20268-K CURRENT REPORT EDGAR
Sep 24, 202625-NSE EDGAR
Sep 4, 2026DEF 14A PROXY STATEMENT EDGAR
Aug 26, 20268-K CURRENT REPORT EDGAR
Aug 24, 2026PRE 14A PROXY STATEMENT EDGAR
Aug 17, 2026SCHEDULE 13G EDGAR
Aug 14, 20268-K CURRENT REPORT EDGAR
Aug 14, 202610-Q QUARTERLY REPORT EDGAR
Aug 5, 2026D EDGAR
Aug 4, 20264 EDGAR
Aug 4, 20264 EDGAR
Aug 4, 20264 EDGAR

The 358 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 55 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Jul 21, 2026Raised $132 million in a private offering of equity Form D: 40 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 45. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Velan Capital Investment Management LP	2,668,395	$1.1M	0.7%	No change
Acorn Capital Advisors, LLC	1,438,159	$604.0K	0.2%	+26,667
Kingdon Capital Management, L.l.c.	1,352,106	$569.2K	0.1%	No change
Vanguard Capital Management LLC	1,172,021	$493.4K	0.0%	−576
Rock Springs Capital Management LP	1,100,726	$463.4K	0.0%	No change
Carlyle Group Inc.	1,066,189	$448.9K	0.0%	No change
Millennium Management LLC	486,933	$205.0K	0.0%	−1,130,598
Lion Point Capital, LP	465,000	$195.8K	0.9%	No change
Geode Capital Management, LLC	263,808	$111.1K	0.0%	−53,869
Renaissance Technologies LLC	237,900	$100.2K	0.0%	+60,400
BlackRock, Inc.	169,627	$71.4K	0.0%	−72,434
Vanguard Fiduciary Trust Co	149,943	$63.1K	0.0%	No change
ADAR1 Capital Management, LLC	140,000	$58.9K	0.0%	No change
Quarry LP	131,529	$55.4K	0.0%	No change
Jane Street Group, LLC	101,743	$42.8K	0.0%	+80,328
UBS Group AG	58,759	$24.7K	0.0%	−22,358
Jain Global LLC	51,185	$21.5K	0.0%	+33,163
Osaic Holdings, Inc.	45,850	$19.3K	0.0%	+5,000
State Street Corp	44,699	$18.8K	0.0%	No change
Northern Trust Corp	41,882	$17.6K	0.0%	+7,306
Diker Management LLC	35,000	$15.0K	0.0%	No change
Qube Research & Technologies Ltd	33,722	$14.2K	0.0%	New
XTX Topco Ltd	33,406	$14.1K	0.0%	−6,025
Simplex Trading, LLC	28,591	$12.0K	0.0%	−682
Ikarian Capital, LLC	24,093	$10.1K	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARJasper Therapeutics, Inc. filings on SEC EDGAR
2
SEC EDGARJasper Therapeutics, Inc. filings on SEC EDGAR
3
SEC EDGARJasper Therapeutics, Inc. 10-K for fiscal 2019
4
SEC EDGARJasper Therapeutics, Inc. 10-K for fiscal 2020
5
SEC EDGARJasper Therapeutics, Inc. 10-K for fiscal 2021
6
SEC EDGARJasper Therapeutics, Inc. 10-K for fiscal 2023
7
SEC EDGARJasper Therapeutics, Inc. 10-K for fiscal 2024
8
SEC EDGARJasper Therapeutics, Inc. 10-Q for fiscal 2026
9
SEC EDGARJasper Therapeutics, Inc. 10-Q for fiscal 2026
10
SEC EDGARJasper Therapeutics, Inc. 10-K for fiscal 2019
11
SEC EDGARJeetinder Singh Mahal, Chief executive officer
12
SEC EDGARRon Martell, Chief executive officer
13
SEC EDGARWilliam Lis, Chief executive officer
14
SEC EDGARBalaji Venkataraman, Chief executive officer
15
SEC EDGARVishal Kapoor, President
16
SEC EDGARHerb Cross, Chief financial officer
17
SEC EDGARJeetinder Singh Mahal, Chief financial officer
18
SEC EDGARKenneth F. Clifford, Chief financial officer
19
SEC EDGARMatthew E. Ros, Chief operating officer
20
SEC EDGARWenru Song, EVP, Head of R&D
21
SEC EDGARGreg Keenan, Chief Medical Officer
22
SEC EDGAREdwin Jonathan Tucker, Chief Medical Officer
23
SEC EDGARWilliam Lis, Officer
24
SEC EDGARJeetinder Singh Mahal, Officer
25
SEC EDGARKevin N. Heller, EVP, Research and Development
26
SEC EDGARPatrick J. Crutcher, Board member
27
SEC EDGARSvetlana Lucas, Board member
28
SEC EDGARVishal Kapoor, Board member
29
SEC EDGARScott C. Brun, Board member
30
SEC EDGARThomas G. Wiggans, Board member
31
SEC EDGARAnna Louise French, Board member
32
SEC EDGARChris Nolet, Board member
33
SEC EDGARJudith Anne Shizuru, Board member
34
SEC EDGARKurt Von Emster, Board member
35
SEC EDGARLawrence Otto Klein, Board member
36
SEC EDGARErnest Mario, Board member
37
SEC EDGARFredric N. Eshelman, Board member
38
SEC EDGARGlenn Reicin, Board member
39
SEC EDGARHoward I. Hoffen, Board member
40
SEC EDGARPeter R. Dolan, Board member